Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations

Original research
par
Cook, R.R. et al

Date de publication

2023

Géographie

USA

Langue de la ressource

English

Texte disponible en version intégrale

Oui

Open Access / OK to Reproduce

Oui

Évalué par des pairs

Yes

L’objectif

Co-use of stimulants and opioids is rapidly increasing. Randomized clinical trials (RCTs) have established the efficacy of medications for opioid use disorder (MOUD), but stimulant use may decrease the likelihood of initiating MOUD treatment. Furthermore, trial participants may not represent “real-world” populations who would benefit from treatment.

Constatations/points à retenir

Stimulant use is a barrier to buprenorphine or XR-NTX initiation in clinical trials and real-world populations that would benefit from OUD treatment.

La conception ou méthodologie de recherche

Analysis using clinical trial data, national survey data, and other datasets

Mots clés

Substitution/OAT
Barriers and enablers
Stimulants
About PWUD